<p>Pacira BioSciences, Inc.（纳斯达克代码：PCRX - 获取免费报告）首席财务官 Shawn Cross 于 12 月 10 日（星期三）出售了 9,104 股公司的股票。股票以平均价格 25.14 美元出售，总交易额为 228,874.56 美元。交易完成后，首席财务官在公司持有 56,250 股，价值 1,414,125 美元。这代表其持股减少了 13.93%。此次出售在向证券交易委员会的备案中披露，具体内容可通过此链接访问。</p>
<p>Shawn Cross 最近还进行了以下交易：</p>
<ul>
<li>在 12 月 9 日（星期二），Shawn Cross 出售了 15,896 股 Pacira BioSciences 的股票。股票以平均价格 25.03 美元出售，总交易额为 397,876.88 美元。</li>
</ul>
<p>获取 <strong>Pacira BioSciences</strong> 的提醒：</p>
<h2>Pacira BioSciences 股票表现</h2>
<p>纳斯达克 PCRX 在星期四上涨 0.55 美元，达到 25.73 美元。该股票的交易量为 1,121,447 股，而其平均交易量为 639,245 股。Pacira BioSciences, Inc.的股价一年低点为 18.17 美元，一年高点为 27.64 美元。公司的 50 日移动平均线为 23.11 美元，200 日移动平均线为 24.15 美元。公司的速动比率为 3.78，流动比率为 5.26，债务股本比率为 0.52。该股票的市值为 11.1 亿美元，市盈率为 57.18，贝塔值为 0.23。</p>
<p>Pacira BioSciences（纳斯达克代码：PCRX - 获取免费报告）最近在 11 月 6 日（星期四）发布了季度财报。公司报告本季度每股收益（EPS）为 0.70 美元，超出市场共识预期的 0.65 美元，超出 0.05 美元。Pacira BioSciences 的股本回报率为 12.82%，净利润率为 2.99%。本季度公司的收入为 1.7952 亿美元，而分析师预期为 1.8286 亿美元。去年同期，该公司每股收益为 0.79 美元。本季度的收入同比增长 6.5%。分析师平均预计 Pacira BioSciences, Inc.在当前年度的每股收益为 2.41 美元。</p>
<h2>对 Pacira BioSciences 的对冲基金看法</h2>
<p>对冲基金最近对该股票的持仓进行了调整。Natixis Advisors LLC 在第一季度购买了 Pacira BioSciences 的新头寸，价值 327,000 美元。US Bancorp DE 在第一季度将其在 Pacira BioSciences 的持股增加了 31.0%。US Bancorp DE 现在持有 2,270 股公司股票，价值 56,000 美元，此前在上个季度购买了 537 股。Charles Schwab Investment Management Inc.在第一季度将其在 Pacira BioSciences 的股份增加了 4.4%。Charles Schwab Investment Management Inc.现在持有 524,486 股公司股票，价值 13,033,000 美元，此前在该期间购买了 22,282 股。Connor Clark &amp; Lunn Investment Management Ltd.在第一季度将其在 Pacira BioSciences 的股份增加了 288.3%。Connor Clark &amp; Lunn Investment Management Ltd.现在持有 171,377 股公司股票，价值 4,259,000 美元，此前在上个季度购买了 127,240 股。最后，Invesco Ltd.在第一季度将其在 Pacira BioSciences 的股份增加了 159.9%。Invesco Ltd.现在持有 624,865 股公司股票，价值 15,528,000 美元，此前在上个季度购买了 384,419 股。目前 99.73% 的股票由机构投资者持有。</p>
<h2>分析师设定新目标价</h2>
<p>PCRX 成为多份研究分析师报告的主题。HC Wainwright 在 11 月 17 日（星期一）的研究报告中重申了对 Pacira BioSciences 的 “买入” 评级，并设定了 38.00 美元的目标价。Zacks Research 在 8 月 14 日（星期四）的研究报告中将 Pacira BioSciences 的评级从 “强烈卖出” 上调至 “持有”。Wall Street Zen 在 11 月 8 日（星期六）的报告中将 Pacira BioSciences 的评级从 “买入” 上调至 “强烈买入”。Weiss Ratings 在周一的报告中重申了对 Pacira BioSciences 的 “卖出（d+）” 评级。最后，Truist Financial 在 11 月 7 日（星期五）的报告中将 Pacira BioSciences 的目标价从 30.00 美元下调至 28.00 美元，并对该公司设定了 “买入” 评级。三位研究分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标价为 28.20 美元。</p>
<p><strong>查看我们最新的 Pacira BioSciences 股票报告</strong></p>
<h2>Pacira BioSciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Pacira Biosciences, Inc.是一家控股公司，专注于提供非阿片类疼痛管理和再生健康解决方案，以改善患者在神经疼痛路径上的体验。其产品包括 EXPAREL、iovera 和 DepoFoam。该公司成立于 2006 年 12 月，总部位于佛罗里达州坦帕。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票比 Pacira BioSciences 更好</li>
<li>如何捕捉股息增加的好处</li>
<li>2026 年应避免的 3 只最近被下调评级的股票</li>
<li>异常交易量的股票：如何实时找到异常交易量的股票</li>
<li>芯片热潮回归：3 只有巨大收益潜力的股票</li>
<li>交易暂停的解释</li>
<li>甲骨文股票受重创：为何其 AI 管道可能推动 2026 年反弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Pacira BioSciences 吗？</h2>
<p>在考虑 Pacira BioSciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Pacira BioSciences 并不在名单上。</p>
<p>虽然 Pacira BioSciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Pacira制药

<p>Pacira 制药首席财务官 Shawn Cross 以每股 25.14 美元的价格出售了 9,104 股，总计 228,874.56 美元，减少了 13.93% 的持股比例。该交易已在 SEC 文件中披露。股票的表现和最近的分析师评级也被讨论，来自不同分析师的评级存在分歧</p>

<p>Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) CFO Shawn Cross sold 9,104 shares of the business's stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $25.14, for a total transaction of $228,874.56. Following the completion of the transaction, the chief financial officer owned 56,250 shares in the company, valued at $1,414,125. This represents a 13.93% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink.</p>
<div class="lb-trans"><p>Pacira BioSciences, Inc.（纳斯达克代码：PCRX - 获取免费报告）首席财务官 Shawn Cross 于 12 月 10 日（星期三）出售了 9,104 股公司的股票。股票以平均价格 25.14 美元出售，总交易额为 228,874.56 美元。交易完成后，首席财务官在公司持有 56,250 股，价值 1,414,125 美元。这代表其持股减少了 13.93%。此次出售在向证券交易委员会的备案中披露，具体内容可通过此链接访问。</p>
</div><p>Shawn Cross also recently made the following trade(s):</p>
<div class="lb-trans"><p>Shawn Cross 最近还进行了以下交易：</p>
</div><ul>
<li>On Tuesday, December 9th, Shawn Cross sold 15,896 shares of Pacira BioSciences stock. The stock was sold at an average price of $25.03, for a total transaction of $397,876.88.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 12 月 9 日（星期二），Shawn Cross 出售了 15,896 股 Pacira BioSciences 的股票。股票以平均价格 25.03 美元出售，总交易额为 397,876.88 美元。</li>
</ul>
</div><p>Get <strong>Pacira BioSciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Pacira BioSciences</strong> 的提醒：</p>
</div><h2>Pacira BioSciences Stock Performance</h2>
<div class="lb-trans"><h2>Pacira BioSciences 股票表现</h2>
</div><p>NASDAQ PCRX traded up $0.55 on Thursday, hitting $25.73. The stock had a trading volume of 1,121,447 shares, compared to its average volume of 639,245. Pacira BioSciences, Inc. has a one year low of $18.17 and a one year high of $27.64. The company's 50-day moving average is $23.11 and its two-hundred day moving average is $24.15. The company has a quick ratio of 3.78, a current ratio of 5.26 and a debt-to-equity ratio of 0.52. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of 57.18 and a beta of 0.23.</p>
<div class="lb-trans"><p>纳斯达克 PCRX 在星期四上涨 0.55 美元，达到 25.73 美元。该股票的交易量为 1,121,447 股，而其平均交易量为 639,245 股。Pacira BioSciences, Inc.的股价一年低点为 18.17 美元，一年高点为 27.64 美元。公司的 50 日移动平均线为 23.11 美元，200 日移动平均线为 24.15 美元。公司的速动比率为 3.78，流动比率为 5.26，债务股本比率为 0.52。该股票的市值为 11.1 亿美元，市盈率为 57.18，贝塔值为 0.23。</p>
</div><p>Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.05. Pacira BioSciences had a return on equity of 12.82% and a net margin of 2.99%.The company had revenue of $179.52 million for the quarter, compared to analysts' expectations of $182.86 million. During the same period last year, the firm earned $0.79 EPS. The firm's revenue for the quarter was up 6.5% on a year-over-year basis. On average, analysts expect that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current year.</p>
<div class="lb-trans"><p>Pacira BioSciences（纳斯达克代码：PCRX - 获取免费报告）最近在 11 月 6 日（星期四）发布了季度财报。公司报告本季度每股收益（EPS）为 0.70 美元，超出市场共识预期的 0.65 美元，超出 0.05 美元。Pacira BioSciences 的股本回报率为 12.82%，净利润率为 2.99%。本季度公司的收入为 1.7952 亿美元，而分析师预期为 1.8286 亿美元。去年同期，该公司每股收益为 0.79 美元。本季度的收入同比增长 6.5%。分析师平均预计 Pacira BioSciences, Inc.在当前年度的每股收益为 2.41 美元。</p>
</div><h2>Hedge Funds Weigh In On Pacira BioSciences</h2>
<div class="lb-trans"><h2>对 Pacira BioSciences 的对冲基金看法</h2>
</div><p>Hedge funds have recently made changes to their positions in the stock. Natixis Advisors LLC purchased a new position in Pacira BioSciences in the first quarter worth $327,000. US Bancorp DE raised its holdings in Pacira BioSciences by 31.0% in the 1st quarter. US Bancorp DE now owns 2,270 shares of the company's stock worth $56,000 after purchasing an additional 537 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Pacira BioSciences by 4.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 524,486 shares of the company's stock worth $13,033,000 after purchasing an additional 22,282 shares during the period. Connor Clark &amp; Lunn Investment Management Ltd. increased its stake in shares of Pacira BioSciences by 288.3% during the first quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 171,377 shares of the company's stock valued at $4,259,000 after purchasing an additional 127,240 shares in the last quarter. Finally, Invesco Ltd. increased its stake in Pacira BioSciences by 159.9% during the 1st quarter. Invesco Ltd. now owns 624,865 shares of the company's stock valued at $15,528,000 after purchasing an additional 384,419 shares in the last quarter. 99.73% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>对冲基金最近对该股票的持仓进行了调整。Natixis Advisors LLC 在第一季度购买了 Pacira BioSciences 的新头寸，价值 327,000 美元。US Bancorp DE 在第一季度将其在 Pacira BioSciences 的持股增加了 31.0%。US Bancorp DE 现在持有 2,270 股公司股票，价值 56,000 美元，此前在上个季度购买了 537 股。Charles Schwab Investment Management Inc.在第一季度将其在 Pacira BioSciences 的股份增加了 4.4%。Charles Schwab Investment Management Inc.现在持有 524,486 股公司股票，价值 13,033,000 美元，此前在该期间购买了 22,282 股。Connor Clark &amp; Lunn Investment Management Ltd.在第一季度将其在 Pacira BioSciences 的股份增加了 288.3%。Connor Clark &amp; Lunn Investment Management Ltd.现在持有 171,377 股公司股票，价值 4,259,000 美元，此前在上个季度购买了 127,240 股。最后，Invesco Ltd.在第一季度将其在 Pacira BioSciences 的股份增加了 159.9%。Invesco Ltd.现在持有 624,865 股公司股票，价值 15,528,000 美元，此前在上个季度购买了 384,419 股。目前 99.73% 的股票由机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>PCRX has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $38.00 price objective on shares of Pacira BioSciences in a research report on Monday, November 17th. Zacks Research upgraded shares of Pacira BioSciences from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, August 14th. Wall Street Zen raised shares of Pacira BioSciences from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, November 8th. Weiss Ratings reiterated a &#34;sell (d+)&#34; rating on shares of Pacira BioSciences in a report on Monday. Finally, Truist Financial decreased their price objective on Pacira BioSciences from $30.00 to $28.00 and set a &#34;buy&#34; rating for the company in a report on Friday, November 7th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $28.20.</p>
<div class="lb-trans"><p>PCRX 成为多份研究分析师报告的主题。HC Wainwright 在 11 月 17 日（星期一）的研究报告中重申了对 Pacira BioSciences 的 “买入” 评级，并设定了 38.00 美元的目标价。Zacks Research 在 8 月 14 日（星期四）的研究报告中将 Pacira BioSciences 的评级从 “强烈卖出” 上调至 “持有”。Wall Street Zen 在 11 月 8 日（星期六）的报告中将 Pacira BioSciences 的评级从 “买入” 上调至 “强烈买入”。Weiss Ratings 在周一的报告中重申了对 Pacira BioSciences 的 “卖出（d+）” 评级。最后，Truist Financial 在 11 月 7 日（星期五）的报告中将 Pacira BioSciences 的目标价从 30.00 美元下调至 28.00 美元，并对该公司设定了 “买入” 评级。三位研究分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标价为 28.20 美元。</p>
</div><p><strong>View Our Latest Stock Report on Pacira BioSciences</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Pacira BioSciences 股票报告</strong></p>
</div><h2>Pacira BioSciences Company Profile</h2>
<div class="lb-trans"><h2>Pacira BioSciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.</p>
<div class="lb-trans"><p>Pacira Biosciences, Inc.是一家控股公司，专注于提供非阿片类疼痛管理和再生健康解决方案，以改善患者在神经疼痛路径上的体验。其产品包括 EXPAREL、iovera 和 DepoFoam。该公司成立于 2006 年 12 月，总部位于佛罗里达州坦帕。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Pacira BioSciences</li>
<li>How to Capture the Benefits of Dividend Increases</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>Trading Halts Explained</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Pacira BioSciences 更好</li>
<li>如何捕捉股息增加的好处</li>
<li>2026 年应避免的 3 只最近被下调评级的股票</li>
<li>异常交易量的股票：如何实时找到异常交易量的股票</li>
<li>芯片热潮回归：3 只有巨大收益潜力的股票</li>
<li>交易暂停的解释</li>
<li>甲骨文股票受重创：为何其 AI 管道可能推动 2026 年反弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=PCRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pacira BioSciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Pacira BioSciences 吗？</h2>
</div><p>Before you consider Pacira BioSciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Pacira BioSciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Pacira BioSciences 并不在名单上。</p>
</div><p>While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Pacira BioSciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

内部人士出售：Pacira BioSciences（NASDAQ:PCRX）的首席财务官出售了 9,104 股股票